Editas Medicine (EDIT) Research & Development (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Research & Development data on file, last reported at $19.8 million in Q3 2025.

• On a quarterly basis, Research & Development fell 58.49% year-over-year to $19.8 million in Q3 2025; TTM through Sep 2025 was $111.2 million, a 49.52% decrease from a year earlier, with the FY2024 full-year figure at $199.2 million, up 12.16% from the prior year.
• Research & Development for Q3 2025 stood at $19.8 million, up from $16.2 million in the prior quarter.
• Over the last five years, Research & Development for EDIT reached as high as $69.6 million in Q4 2023 and fell as low as $16.2 million in Q2 2025.
• Historically, Research & Development has averaged $39.8 million across 5 years, with a median of $40.5 million in 2023.
• Across the five-year window, Research & Development surged 82.04% in 2024 and slumped 70.15% in 2025, its largest moves.
• Year by year, Research & Development stood at $37.6 million in 2021, then soared by 38.47% to $52.0 million in 2022, then jumped by 33.77% to $69.6 million in 2023, then sank by 30.11% to $48.6 million in 2024, then plunged by 59.32% to $19.8 million in 2025.
• Per Business Quant data, the three most recent Research & Development figures were $19.8 million in Q3 2025, $16.2 million in Q2 2025, and $26.6 million in Q1 2025.